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patients 50 years of age
treated with SRS alone. Also
in this cohort, no apparent
increase was observed in the
risk of new brain metastases.
SRS alone is supported in
patients presenting with up
to 4 brain metastases.survival, age was a significant effect modifier (PZ.04) favoring SRS alone in patients
50 years of age, and no significant differences were observed in older patients. Haz-
ard ratios (HRs) for patients 35, 40, 45, and 50 years of age were 0.46 (95% confidence
interval [CI] Z 0.24-0.90), 0.52 (95% CI Z 0.29-0.92), 0.58 (95% CI Z 0.35-0.95),
and 0.64 (95% CI Z 0.42-0.99), respectively. Patients with a single metastasis had
significantly better survival than those who had 2 to 4 metastases. For distant brain
failure, age was a significant effect modifier (PZ.043), with similar rates in the 2 arms
for patients 50 of age; otherwise, the risk was reduced with WBRT for patients
>50 years of age. Patients with a single metastasis also had a significantly lower risk
of distant brain failure than patients who had 2 to 4 metastases. Local control signif-
icantly favored additional WBRT in all age groups.
Conclusions: For patients 50 years of age, SRS alone favored survival, in addition,
the initial omission of WBRT did not impact distant brain relapse rates. SRS alone
may be the preferred treatment for this age group.  2015 Elsevier Inc.Introduction
Management of patients presenting with a limited number
of brain metastases has evolved from whole-brain radiation
(WBRT) alone to more aggressive management incorpo-
rating stereotactic radiosurgery (SRS) (1, 2). SRS refers to
a single dose of radiation delivered with high precision
focally to a brain metastasis with the intent of maximizing
local control while sparing normal brain tissue. Thus far,
there have been 3 completed published randomized
controlled trials (RCTs) comparing SRS alone to SRS plus
WBRT in patients presenting with 1 to 4 brain metastases
(3-5). Although the inclusion criteria were relatively uni-
form among the trials, the primary endpoints were incon-
sistent and not designed for survival (1). Endpoints
included brain tumor recurrence (3), maintenance of a
World Health Organization (WHO) performance status
(PS) of at least 2 (5), and neurocognitive functioning as
measured using the Hopkins Verbal Learning Test (4).
Although each of the RCTs reported consistent and sig-
nificant gains in both local control and distant brain control
with additional WBRT, the impact on survival was con-
flicting (1).
Without any clear understanding of the treatment effect
on survival, current clinical decision making with respect to
offering patients SRS alone or SRS plus WBRT is largely
based on physician and patient preferences. The purpose of
this study was to pool individual patient data (IPD) from 3
RCTs (3-5) and conduct an IPD meta-analysis to evaluate
efficacy of SRS, with or without WBRT, for patients pre-
senting with 1 to 4 brain metastases with respect to sur-
vival, local failure, and distant brain failure.Methods and Materials
Randomized Trial Selection Process
A search of publications was performed for English-
language articles published from January 1980 throughJanuary 2014 in the PubMed electronic database, using the
search terms brain metastases, brain tumors, randomized
controlled trials, whole-brain radiation therapy, stereotactic
radiation surgery, surgery, and radiation surgery. We also
examined the reference sections of published meta-analyses
and reviews to identify relevant RCTs (1, 6). Only those
RCTs where comparisons consisted of an SRS-alone arm to
a SRS plus WBRT arm were selected for review. The
selected RCTs had to have met complete accrual criteria in
accordance with the original study’s primary endpoint, or
had to have criteria for a modified endpoint at interim
analysis, or terminated early due to early stopping rules by
the data safety monitoring board due to a priori criteria
such that the study endpoint would otherwise be reached.
This resulted in a final selection of 3 RCTs (3-5), and the
IPD were obtained from each trial based on the published
results from the corresponding authors. Figure 1 summa-
rizes the literature search approach.
Participants
The first of the 3 RCTs was reported by Aoyama et al
(JROSG99-1) in 2006 (3). In that study, 132 patients with 1
to 4 brain metastases were randomized to receive SRS or
SRS plus WBRT. Although that trial was initially powered
for survival, accrual was terminated at the interim analysis
when it was realized that the sample size for survival would
be unachievable; however, the sample was sufficient to
determine a difference in brain tumor recurrence rates. The
Chang et al MD Anderson Cancer Center trial
(www.clinicaltrials.gov identifier NCT00548756) was
subsequently reported in 2009 (4). In that study, 58 patients
with 1 to 3 brain metastases were randomized to receive
SRS or SRS plus WBRT. That trial was powered to deter-
mine a difference in the neurocognitive outcome of total
recall. The trial was terminated before the planned sample
size, as early stopping rules confirmed superiority in the
SRS-alone cohort compared to those treated with SRS plus
WBRT. The Kocher et al European Organization for
Research and Treatment of Cancer (EORTC) trial 22952-
Fig. 1. Flowchart of trials included in the meta-analysis.
SRS Z stereotactic radiosurgery; RCT Z randomized
controlled trial; WBRT Z whole-brain radiation therapy.
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with 1 to 3 brain metastases from which a total of 199
patients were treated with SRS as opposed to 160 patients
who were treated with surgery. Patients were then ran-
domized to receive WBRT or observation (5). Only the 199
patients initially treated with SRS were included in this IPD
meta-analysis. That trial was powered to determine a dif-
ference in the proportion of patients alive at 6 months with
a WHO PS of 0 to 2. Overall, the EORTC study was
completed according to its intended statistical design (5).
The study populations within each RCT were relatively
consistent such that each tumor was eligible for SRS, (as
confirmed by baseline magnetic resonance imaging) patient
18 years of age, and radiosensitive tumors (i.e. hemato-
logic, small-cell, germ cell) were excluded. With respect to
performance status, the inclusion criteria for each trial
stipulated a Karnofsky performance status (KPS) 70, and/
or a WHO PS of 0 to 2, and/or a recursive partitioning
analysis (RPA) class of 1 or 2 (RPA class 1 refers to
controlled primary disease, <65 years of age, KPS of 70,
and no extracranial metastases; RPA class 2 refers to a KPS
of 70 and any combination of controlled primary disease,
age, and extracranial metastases; and RPA class 3 refers to
KPS of <70) (7). Upon review of the IPD, we identified 25
patients with a KPS of <70 (RPA class 3). We chose to
exclude those patients as it has been consistently observed
that PS is among the most powerful predictors of survival
(7). As a result, the pooled analysis consisted of 364 of the
eligible 389 patients. Of note, 2 of the 3 RCTs allowed up
to 3 metastases (4, 5), with only the Aoyama trial (3)
allowing up to 4 metastases. We did not exclude patients
with 4 metastases as this factor is less likely to impact
survival, and a recent phase 2 study confirmed no survivaldisadvantage in patients presenting with 2 to 4 versus 5 to
10 metastases (8).Statistics
A 1-stage time-to-event IPD meta-analysis approach was
performed, fitting a hierarchical Cox regression model (9).
The 1-stage meta-analytic method has the advantage that
potential confounders and prognostic factors can be
adjusted, compared to the more traditional 2-stage
approach. In addition, interaction terms can be explored if
there are imbalances between treatment arms within a
study, or if differences across studies might be a concern or
cause of heterogeneity (10-12). In a 2-stage analysis, ad-
justments might not be effective especially in small, indi-
vidual studies of IPD data, or even possible (differences
across studies would not be taken in to account) if the
summary data are extracted from published reports (10-12).
We used the mixed-effects Cox regression modeling
approach, using mixed-effects Cox models R software, with
the assumptions of random study effects (random intercept
per study) and random treatment effects (across studies) for
each outcome of survival, local failure and distant brain
failure. Besides the treatment variable (SRS alone vs SRS
plus WBRT), we a priori included 3 covariates: age, RPA
class 1 versus 2, and number of brain metastases (1 vs 2)
in the multivariate model. These covariates are known
important prognostic factors, and were collected at baseline
in all 3 RCTs. The interaction term of any of these cova-
riates with treatment was also included in the model if such
an interaction term remained significant with a P value
of  .05 in the multivariate adjusted analysis. The methods
within each trial were followed with respect to defining
local failure, distant brain failure and neurologic death;
event status and time to event was based on initial failure
date.Results
The baseline statistics in the 3 selected RCTs, with a total of
364 eligible patients, as well as the distribution of local
failure, distant brain failure, all-cause mortality, and neuro-
logic death are summarized in Table 1. Of the 364 patients,
186 (51%) were treated with SRS alone and 178 (49%) with
SRS plus WBRT. In the SRS-alone and SRS plus WBRT
cohorts, the median (lower, upper quartile) time to death
was 10 months (4.5, 18) and 8.2 months (4, 13), respectively,
and the mean (SD) time to death was 15 months
(16 months) and 14 months (14 months), respectively. In
the respective cohorts, the median (lower, upper quartile)
time to local failurewas 6.6 (3.4, 14)months and 7.4 (3.8, 16)
months, respectively, and the mean (SD) time to local
failure was 11 (14) versus 13 (13) months, respectively.
Themedian (lower, upper quartile) time to distant failurewas
4.7 months (2.8, 11) and 6.5 months (3.8, 16), and the mean
Table 1 Descriptive statistics for 364 patients and those stratified by SRS versus SRS plus WBRT age groups
Factor
Total no. of
patients
(nZ364)
SRS alone
(nZ186)
SRS plus
WBRT
(nZ178)
SRS alone
age >50 yr
(nZ155)
SRS plus WBRT
age >50 yr
(nZ141)
SRS alone
age 50 yr
(nZ31)
SRS plus WBRT
age 50 yr
(nZ37)
No. of females/
males (%/%)
128/236 (35/65) 65/121 (35/65) 63/115 (35/65) 47/108 (30/70) 47/94 (33/67) 18/13 (58/42) 16/21 (43/57)
Median age, yr
(range)
62 (33-86) 62 (33-86) 61 (35-78) 64 (51-86) 65 (51-78) 45 (33-50) 45 (35-50)
Age 50 yr (%) 68 (19%) 31 (17%) 37 (21%)
RPA1/RPA2 (%/%) 149/215 (41/59) 73/113 (39/61) 76/102 (43/57) 56/99 (36/64) 50/91 (35/65) 17/14 (55/45) 26/11 (70/30)
No. of brain metastases (%)
1 217 (60%) 111 (60%) 106 (60%) 92 (59%) 80 (57%) 19 (61%) 26 (70%)
2 88 (24%) 44 (24%) 44 (25%) 36 (23%) 36 (26%) 8 (26%) 8 (22%)
3 47 (13%) 24 (13%) 23 (13%) 21 (14%) 21 (15%) 3 (10%) 2 (5%)
4 12 (3%) 7 (4%) 5 (3%) 6 (4%) 4 (3%) 1 (3%) 1 (3%)
Extracranial
metastases
202 (56%) 100 (54%) 102 (58%) 82 (52%) 77 (55%) 18 (58%) 25 (68%)
Cancer type
Lung 214 (59%) 109 (59%) 105 (59%) 100 (65%) 84 (60%) 9 (29%) 21 (57%)
Breast 43 (12%) 22 (12%) 21 (12%) 12 (8%) 11 (8%) 10 (32%) 10 (27%)
Kidney 24 (6%) 11 (6%) 13 (7%) 6 (4%) 13 (9%) 5 (16%) 0 (0%)
Other 83 (23%) 44 (23%) 39 (22%) 37 (24%) 33 (23%) 7 (23%) 6 (16%)
Local failures (%) 72 (20%) 51 (27%) 21 (12%) 41 (26%) 17 (12%) 10 (32%) 4 (11%)
Salvage
treatment
after local
failures (%)
45 (63%) 37 (73%) 8 (38%) 29 (71%) 7 (41%) 8 (80%) 1 (25%)
Distant brain
failures (%)
156 (43%) 98 (53%) 58 (34%) 78 (50%) 39 (28%) 20 (65%) 19 (51%)
Salvage treatment
after distant
failures (%)
100 (64%) 72 (73%) 28 (48%) 56 (72%) 19 (49%) 16 (80%) 9 (47%)
Total deaths (%) 314 (86%) 157 (84%) 157 (88%) 135 (87%) 126 (89%) 22 (71%) 31 (84%)
Neurologic
deaths (%)
99 (27%) 55 (30%) 44 (25%) 43 (28%) 36 (26%) 12 (39%) 8 (22%)
Abbreviation: RPA Z recursive partitioning analysis.
Volume 91  Number 4  2015 Radiation surgery for brain metastases 713(SD) time to distant brain failure was 9.6 months
(13 months) versus 12 months (12 months), respectively.
Patient age as a continuous variable was found to be a
significant treatment effect modifier on survival (PZ.04 for
the interaction term); which means that the treatment effect
on survival differs for patients with different ages. From the
fitted regression model with the interaction term, estimates
of the adjusted hazard ratios (HRs) and corresponding 95%
confidence intervals (CI) of treatment effects on survival
(SRS vs SRS plus WBRT) were calculated and shown at 35
to 80 years of age in 5-year intervals (Table 2, Fig. 2). As
shown in Table 2 and Figure 2, patients 50 years of age
initially treated with SRS alone had a significantly lower
hazard of mortality than patients with similar ages treated
with SRS plus WBRT. However, there were no significant
differences in mortality between the 2 treatment groups for
patients >50 years of age (Table 2 and Fig. 2). For patients
50 years of age, the median survival was 13.6 months in
the SRS-alone cohort as opposed to 8.2 months in the SRS
plus WBRT cohort. The median survival was 10.1 monthsand 8.6 months for patients >50 years of age treated with
SRS alone and SRS plus WBRT, respectively. Based on our
finding of treatment benefit of SRS alone on survival for
patients 50 years of age, we also summarized the baseline
characteristics of 296 patients >50 years of age and 68
patients 50 years of age in Table 1. Of note with respect to
histology, other than a greater proportion of renal cell
carcinoma patients in the cohort of SRS-alone patients
50 years of age, compared to the cohort of SRS plus
WBRT patients 50 years of age, there were no signifi-
cant differences between groups (P>.05). In keeping with
survival analyses and our other a priori-selected covariates,
we also observed a statistically significant lower hazard of
mortality among patients with 1 metastasis as compared to
those with 2 metastases (HR Z 0.72, 95% CI Z 0.57-
0.90), and among patients with RPA class of 1 as compared
to class 2 (HR Z 0.75, 95% CI Z 0.56-0.99).
Patient age as a continuous variable was also found to be
a significant treatment effect modifier on distant brain
failure (PZ.04 for the interaction term); which means that
Table 2 Hazard ratio estimates for SRS alone versus SRS
plus WBRT at different ages for overall survival and distant
brain failure
Age*
HR (95% CI) fory
Overall survival Distant brain failure
35 0.46 (0.24-0.9) 0.90 (0.42-1.94)
40 0.52 (0.29-0.92) 1.05 (0.56-1.98)
45 0.58 (0.35-0.95) 1.23 (0.73-2.05)
50 0.64 (0.42-0.99) 1.43 (0.95-2.15)
55 0.72 (0.49-1.05) 1.67 (1.19-2.35)
60 0.80 (0.56-1.14) 1.95 (1.40-2.71)
65 0.90 (0.62-1.29) 2.27 (1.55-3.33)
70 1.0 (0.67-1.49) 2.65 (1.64-4.27)
75 1.12 (0.71-1.76) 3.09 (1.70-5.61)
80 1.24 (0.73-2.11) 3.60 (1.75-7.44)
Abbreviations: CI Z confidence interval; HR Z hazard ratio.
* Because treatment effect depends on the patient’s age (as it was a
significant effect modifier), estimates of effects (HRs and corre-
sponding 95% CIs) are presented at patients’ ages from 35 to 80 years
at intervals of 5 years.
y Estimates were obtained from adjusted analysis for important
confounders and prognostic factors. Significant estimates (boldface)
with HR < 1 and HR > 1 suggest protective and harmful effects,
respectively, of SRS alone at the corresponding age on the respective
outcome.
Fig. 3. Estimates of treatment effects (SRS vs SRS plus
WBRT) and corresponding 95% CIs on distant brain con-
trol at 35 to 80 years of age at 5-year intervals.
SRS Z stereotactic radiosurgery; WBRT Z whole-brain
radiation therapy.
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tients with different ages. From the fitted regression model
with the interaction term, estimates of the adjusted HRs and
corresponding 95% CIs of treatment effects (SRS vs SRS
plus WBRT) on distant brain failure were calculated and
shown at 35 to 80 years of age in 5-year intervals (Table 2,
Fig. 3). The risk of distant brain failure for all patients
50 years of age initially treated with SRS alone was notFig. 2. Estimates of treatment effects (SRS vs SRS plus
WBRT) and corresponding 95% CIs on survival at 35 to
80 years of age at 5-year intervals. SRS Z stereotactic
radiosurgery; WBRT Z whole-brain radiation therapy.significantly different from that for those initially treated
with SRS plus WBRT. Beyond age 50, the risk of distant
failure was significantly higher for all patients in the SRS-
alone cohort than in the SRS plus WBRT cohort. Patients
with 1 metastasis had a significantly lower risk of devel-
oping distant brain failure than those with 2 metastases
(HR Z 0.63, 95% CI Z 0.46-0.88). No significant rela-
tionship was observed for RPA class 1 versus 2 (HR Z
0.79, 95% CI Z 0.56-1.14).
For local brain failure analysis, treatment effect was not
modified significantly by any of the covariates. The esti-
mate of HR was 1.01 (95% CIZ 0.98-1.03) for every year
of increase in patient age, 0.74 (95% CI Z 0.46-1.18) for
number (1 vs 2) of brain metastases, and 1.28 (95%
CI Z .0.76-2.17) for RPA class 1 versus 2. The analysis
model with no interaction term revealed that SRS plus
WBRT was associated with a lower hazard of local brain
failure than SRS alone (HRZ 2.56, 95% CIZ 1.54-4.26).
A total of 63% (45 of 72) of local failures and 64% (100
of 156) of distant failures underwent salvage treatments
(Table 1). Although there were more failures and salvage
treatments in those treated with SRS alone versus SRS plus
WBRT (Table 1), there were no statistically significant
differences in the proportions of salvage treatment for local
and distant failures according to patient age groups within
corresponding treatment arms (for example, in patients
>50 years of age treated with SRS alone, 71% of local
failures were salvaged as compared to 80% in patients
50 years of age treated with SRS alone) (Table 1).
Moreover, the median survival times for those undergoing
any salvage brain therapy was 18.2 months and
16.2 months in patients  50 years of age compared with
those >50 years of age, respectively. Median survivals for
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7.0 months and 5.9 months in patients  50 years of age
compared with those >50 years of age, respectively. With
respect to neurologic death (Table 1), there were no sta-
tistically significant differences among the cohorts. Of note,
the number of neurologic deaths was greater in the SRS-
alone cohort for patients 50 years of age versus those in
the SRS plus WBRT cohort 50 years of age, at 39%
versus 22%, respectively, although the comparison was not
statistically significant.
A post hoc sensitivity analysis was performed to deter-
mine whether data from any 1 trial confounded the results.
When we performed a step-wise exclusion of any of the 3
data sets, the estimates of treatment effects were not sig-
nificant, but the directions were consistent with that
observed when analyzing the entire data. Therefore, no
single randomized trial impacted the result.Discussion
Considering each of the RCTs included in this IPD meta-
analysis comparing SRS alone to SRS plus WBRT (3-5),
prior meta-analysis based on aggregate published data
(1, 6), and prior studies evaluating the addition of SRS plus
WBRT with systemic agents or surgery (13-22), it has been
consistently observed that in patients presenting with a
limited number of brain metastases, the addition of WBRT
increases both local control and distant brain control. In
these trials, the limited sample sizes prevented subset
analysis and we assumed, with respect to these 2 specific
endpoints, that the benefits of WBRT were uniform within
the study populations.
With respect to survival, we have previously learned that
in patients with an expected long-term survival, such as
those presenting with 1 metastasis and an RPA of 1, that
strategies to optimize local control (additional surgery or
SRS to WBRT) can yield survival benefits when the alter-
native treatment is WBRT alone (16, 17). However, in the
SRS-alone versus SRS plus WBRT trials (where local
control is optimized in both arms by SRS), the impact on
survival has not been clear. Both the Aoyama et al (3) and
Kocher et al (5) trials reported no survival advantage to
additional WBRT, whereas the Chang et al (4) trial reported
a survival advantage favoring SRS alone. Importantly, none
of these trials were intended to address survival as the
primary endpoint.
By performing an IPD meta-analysis, we were able to
perform subset analyses and report age as a significant
treatment effect modifier with respect to both survival and
distant brain control. In those patients 50 years of age, a
survival advantage was observed with SRS alone compared
to their age-matched cohort treated with SRS plus WBRT
(Table 2, Fig. 2). For patients older than 50 years of age no
survival disadvantage was observed with SRS alone. With
respect to distant brain failure, patients 50 years of age
treated with SRS alone had no increased risk of developingnew brain metastases compared to their age-matched cohort
treated with SRS plus WBRT (Table 2, Fig. 3). Beyond age
50, the risk of new distant brain metastases was signifi-
cantly greater in patients treated with SRS alone. Age was
not a treatment effect modifier for local failure, and addi-
tional WBRT reduced the risk of local tumor failure. We
also observed that patients presenting with 1 metastasis had
a favorable survival and a lower risk of distant brain failure
than patients with 2 to 4 metastases, and that patients with
an RPA 1 versus 2 had favorable survival. These latter
findings are in excellent agreement with those of published
reports (7, 8, 17).
Although this IPD meta-analysis could not analyze the
toxicity aspects of the treatment arms, there are now
randomized studies that clarify the adverse effects of
WBRT. It is now clear, based on a randomized study
evaluating prophylactic cranial irradiation in patients with
nonesmall-cell lung cancer, that WBRT leads to a decline
in memory function despite a reduction in the incidence of
new brain metastases (23). Unfortunately, the trial could
not accrue sufficiently for the endpoint of survival (23).
The association between WBRT and adverse neuro-
cognitive outcomes in patients treated upon the develop-
ment of brain metastases has also been reported by Chang
et al (4). This trial concluded that the addition of WBRT to
SRS results in significantly worse memory function than
SRS alone despite a reduction in intracranial relapse rates.
Clearly these studies show that WBRT is independently
compromising neurocognition. With respect to quality of
life (QOL), we have recently learned from the EORTC
RCT comparing observation versus WBRT, after either
SRS or surgery, that the addition of WBRT results in
worse QOL outcomes (24). This finding may be critical
given the results of a QOL analysis, from a RCT
comparing high-dose radiation for lung cancer primary
tumors to lower dose radiation (with chemotherapy),
reported in abstract form (25). The high-dose radiation
arm yielded a clinically meaningful decline in QOL and
survival compared to the low-dose arm. The authors
postulate that the decline in QOL, as a patient-reported
outcome, may explain the negative survival result even
though provider related toxicities were not significantly
different (25).
Given the recent data confirming harm to cognition and
QOL with WBRT (2,23,24), and the potential for a survival
detriment when compromising QOL (25), we hypothesize
that in patients 50 years of age that exposure to the
adverse effects of WBRT without yielding a therapeutic
gain with respect to distant brain relapse rates (no signifi-
cant difference in distant brain failure was observed in these
younger patients when treated with SRS alone vs SRS plus
WBRT) (Table 2, and Fig. 3) may explain our survival
results. Note that when WBRT reduced the rate of new
brain metastases, as observed in the older patients (age >50
years, Figure 3, Table 2) treated with SRS plus WBRT vs
SRS alone, no survival advantage or disadvantage was
observed between the two arms.
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and an area of further investigation; however, there are un-
controlled and limited data emerging that also report the
association between treatment with SRS alone and favorable
survival rates compared to treatment with WBRT (26, 27).
We also acknowledge that the observation of distant brain
failure rates being no greater in the younger patients, despite
the lack of WBRT, and the implication on survival remain to
be explained. Biomarkers, nomograms, and new imaging
techniques to identify those patients not at risk of distant
brain failure is an active area of investigation, and may assist
in the selection of patients best suited for SRS alone.
Potential limitations of this study include an observed
imbalance in the primary cancer type in patients 50 years
of age treated with SRS versus SRS plus WBRT. There
were patients 50 years of age with a renal cell primary
treated in the SRS-alone cohort compared to those
50 years of age treated with SRS plus WBRT (Table 1).
When we analyzed the effect of this factor by excluding
these patients, the same trends were observed as those of
our reported results for the entire sample. An analysis was
also performed to determine whether our result would hold
true when considering only the lung cancer and breast
cancer cohorts, given that there were higher numbers of
lung cancer patients in the SRS plus WBRT cohort and
breast cancer patients in the SRS-alone cohort, even though
the differences were nonsignificant (P>.05). The analysis
yielded the same trends with respect to our reported
results for the entire sample. Caution must be observed in
histology-specific subset analyses as they are limited in
terms of sample size, and considered exploratory with the
intent to confirm trends in the outcome direction. There-
fore, firm histology-specific conclusions cannot be drawn.
Of note, there was a greater proportion of RPA1 to RPA2
patients in younger patients (50 years) treated with SRS
plus WBRT than the SRS-alone cohort (Table 1); however,
the difference was not statistically significant.
Ultimately, what is required are histology-specific trials
for brain metastases, and these are challenging due to the
potential for numerous factors to influence outcomes in the
metastatic patient. For example, variability in terms of the
sites and numbers of extracranial organs involved, patients
being at different points in the trajectory of their disease (ex
oligometastatic or a diffuse disease pattern) and the het-
erogeneity with respect to exposure (or to be exposed) to
various systemic therapies with some now having activity
in the brain. Of note, a recent large study of 1194 patients
treated with SRS alone for 1 to 10 metastases also did not
observe significant differences in survival when comparing
the primary cancer types of breast versus lung, renal cell
versus lung, others versus lung, with the exception of pa-
tients with gastrointestinal primaries versus lung primaries
(8). In that study, the authors also examined the rate of
distant brain failure and overall survival in patients with 2
to 4 versus 5 to 10 metastases treated with SRS alone. They
observed no significant differences in either outcome. This
is important as our conclusions are made for patients withup to 4 metastases even though only one of the 3 RCTs in
this meta-analysis included patients with 4 metastases.
However, we acknowledge that our results may be more
applicable to those presenting with up to 3 metastases as
only the minority of patients had 4 metastases (Table 1).
With respect to salvage therapy, there were more re-
lapses in the SRS-alone cohorts both locally and distantly,
and more salvage treatments (Table 1). We observed that
patients who were treated with brain salvage treatments, as
opposed to no brain salvage treatments, had longer survival.
No statistically significant differences in the proportion of
patients receiving salvage therapy with respect to age
within corresponding treatment arms (Table 1) were
observed, and the same impact on survival in those treated
with salvage versus no salvage according to age was
observed. Therefore, although we could not obtain the
needed information as to what local/distant salvage thera-
pies were delivered, the extra cranial disease status at the
time of relapse, PS at the time of brain relapse and details
with respect to chemotherapy delivery or molecular status
of the primary, we acknowledge that these are RCTs with
the expectation that unforeseen factors causing bias
downstream from the initial treatment were accounted for
by the randomization. Furthermore, most of the prognostic
factors that were available from all 3 studies were similarly
distributed in the 2 treatment arms as well as sub groups of
age; therefore, we expect that any impact due to residual
imbalances including that of salvage treatment in the IPD
meta-analysis would have minimal impact on the estimates
of treatment effects. We also acknowledge that there was a
non-significant difference in the number of neurologic
deaths in younger patients (50 years of age) treated with
SRS alone versus SRS plus WBRT (Table 1), which may be
a drawback to both the increased local/distant failure rates
and use of salvage procedures when treating with SRS
alone, despite the overall survival results. However, the
sample is limited, and there is subjectivity in neurologic
death assessments compared to the harder endpoints of
local control, distant brain control, and overall survival.
Conclusions
In conclusion, based on the use of SRS alone as initial
therapy for patients with 1 to 4 brain metastases, this IPD
meta-analysis suggests (with the above caveats taken into
consideration) a survival advantage in patients 50 years of
age; in addition, the initial omission of WBRT did not
adversely impact distant brain relapse rates in this cohort.
SRS alone may be the preferred treatment for this age
group.
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